Detection Of ctDNA With Assay Linked To Disease Recurrence In Patients With HR-Positive, HER2-Negative Early Breast Cancer, Analysis Finds

OncLive (12/6, Killmurray) reports “detection of circulating tumor DNA (ctDNA) with the SignateraTM assay was associated with disease recurrence in patients with hormone receptor (HR)–positive, HER2-negative, node-positive, high-risk early breast cancer at 24 months post-randomization to treatment with adjuvant abemaciclib (Verzenio) and endocrine therapy, according to an analysis.” The findings were presented at the San Antonio Breast Cancer Symposium.